Liveyon suspended sales of its stem cell product a week after being warned by the Food and Drug Administration that it was selling an unapproved product that posed serious risks. The product derives stem cells from umbilical cord blood.
By By Dino GrandoniLaurie McGinley, Washington Post
Thu, 12/12/2019 - 11:44pm
Liveyon suspended sales of its stem cell product a week after being warned by the Food and Drug Administration that it was selling an unapproved product that posed serious risks. The product derives stem cells from umbilical cord blood.